Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N α(2α)-adrenoceptor transgenic mice

British Journal of Pharmacology

Volumn 126, Issue 6, 1999, Pages 1522-1530

  Zhu, Q M ^a   Lesnick, J D ^a   Jasper, J R ^a   MacLennan, S J ^a   Dillon, M P ^a   Eglen, R M ^a   Blue Jr , D R ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Clonidine; Imidazoline receptors; Moxonidine; Rilmenidine; RS 79948 197; 2 adrenoceptors

Indexed keywords

12 ETHYLSULFONYL 5,8,8A,9,10,11,12,12A,13,13A DECAHYDRO 3 METHOXY 6H ISOQUINO[2,1 G][1,6]NAPHTHYRIDINE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; CLONIDINE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MOXONIDINE; NORADRENALIN; RECOMBINANT RECEPTOR; RILMENIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BRADYCARDIA; CARDIOVASCULAR EFFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; HEART RATE; HUMAN; HUMAN CELL; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SAPHENOUS VEIN; TRANSGENE;

EID: 0032999257     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702429     Document Type: Article

References (40)

1. BOUSQUET, P. (1997). Commentary imidazoline receptors. Neurochem. Int., 30, 3-7.
2. BOUSQUET, P., FELDMAN, J., BLOCH, R. & SCHWARTZ, J. (1981). The nucleus reticularis lateralis: a region highly sensitive to clonidine. Eur. J. Pharmacol, 69, 389-392.
3. BROWN, C.M., MACKINNON, A.C., REDFERN, W.S., HICKS, P.E., KILPATRICK, A.T., SMALL, C., RAMCHARAN, M., CLAGUE, R.U., CLARK, R.D., MACFARLANE C.B. & SPEDDING, M. (1993). The pharmacology of RS-15385-197, a potent and selective OE2-adrenoceptor antagonist. Br. J. Pharmacol., 108, 516-525.
4. 2 adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats. J. Pharmacol. Exp. Ther., 273, 1162-1171.
5. CHAN, C.K.S. & HEAD, G.A. (1996). Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and remenidine. J. Hyperten., 14, 855-864.
6. 1) and the concentration of inhibitor which causes 50 percent inhibition of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108.
7. 1A receptors in human cerebral cortex. Eur. J. Pharmacol., 159, 307-310.
8. 2-adrenoceptors in he human central nervous system. Neuroscience, 59, 589-598.
9. EGLEN, R.M., HUDSON, A.L., KENDALL, D.A., NUTT, D.J., MORGAN, N.G., WILSON, V.G. & DILLON, M.P. (1998) 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol. Sci., 19, 381-390.
10. ERNSBERGER, P., ELLIOTT, H.L., WEIMANN, H.-J., RAAP, A., HAXHIU, M.A., HOFFERBER, E., LÖW-KRÖGER, A., REID, J. & MEST, H.-J. (1993). Moxonidine: a second-generation central antihypertensive agent. Cardiovas. Drug Rev., 11, 411-431.
11. 1-imidazoline receptors definition, characterization, distribution, and transmembrane signaling. Ann. N. Y. Acad. 763,22-42.
12. 1-imidazoline binding site is a functional receptor mediating vasodepression viathe ventral medulla. Am. J. Physiol., 273, R1572-R1579.
13. GUYENET, P.G. (1997). Is the hypotensive effect of clonidine and related drugs due to imidazoline binding sites? Am. J. Physiol., 273, R1580-R1584.
14. 1-imidazoline agonist moxonidine administered into the rostral ventrolateral medulla, J. Cardiovas. Pharmacol., 20, S11-S15.
15. HEAD, G.A., GODWIN, S.J. & SANNAJUST, F. (1993). Differential receptors involved in the cardiovascular effects of clonidine and rilmenidine in conscious rabbits. J. Hypertension, 11, S322-S323.
16. 2-adrenoceptors. Br. J. Pharmacol., 110, 1635-1639.
17. 2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br. J. Pharmacol., 122, 1339-1344.
18. 35S]GTPyS binding. Biochem. Pharmacol., 55, 1035-1043.
19. 2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc. Natl. Acad. Sci., 94: 9950-9955.
20. 2-adrenoceptor-subtype function. Trends Pharmacol. Sci., 118, 211-219.
21. 2Asubtype. Br. J. Pharmacol., 121, 1721-1729.
22. 2a-adrenergic receptor subtype. Science, 273, 801-803.
23. 2A-adrenergic receptor by homologous recombination reveals the role of this receptor subtype in multiple physiological processes. Adv. Pharmacol., 42, 493-496.
24. 2-adrenoceptors in the canine saphenous vein. Fundam. Clin. Pharmacol., 10, 379-385.
25. 2-adrenoceptor subtypes. Ann. N.Y. Acad. Sci., 812, 176-177.
26. 1-adrenergic receptor subtypes. Mol. Pharmacol., 46, 929-936.
27. PRICHARD, B.N.C., OWENS, C.W.I. & GRAHAM, B.R. (1997). Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. J. Hum. Hyperten., 11, S29-S45.
28. REIS, D.J. (1996). Neurons and receptors in the rostroventrolateral medulla mediating the antihypertensive actions of drugs acting at imidazoline receptors. J. Cardiovas. Pharmacol., 27, S11-S18.
29. SCHMITT, H., SCHMITT, H. & FENARD, S. (1973). Action of α-adrenergic blocking drugs on the sympathetic centres and their interactions with the central sympatho-inhibitory effect of clonidine. Arzneim-Forsch. (Drug Res.), 23, 40-45.
30. STORNETTA, R.L., HUANGFU, D., ROSIN, D.L., LYNCH, K.R. & GUYENET, P.G. (1995). Alpha-2 adrenergic receptors immuno-histochemical localization and role in mediating inhibition of adrenergic RVLM presympathetie presympathetic neurons by catecholamines and clonidine. Ann. N.Y. Acad. Sci., 763, 541-551.
31. 2-adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G protein state. Mol. Pharmacol., 45, 524-531.
32. TIBIRICA, E., FELDMAN, J., MERMET, C., GONON, F. & BOUSQUET, P. (1991). An imidazoline-specific mechanism for the hypotensive effect of clonidine: a study with yohimbine and idazoxan. J. Pharmacol. Exp. Ther., 256, 606-613.
33. TIMMERMANS, P.B.M.W.M., SCHOOP, A.M.C., KWA, H.Y. & VAN ZWIETEN, P.A. (1981). Characterization of α-adrenoceptors participating in the cetral hypotensive and sedative effects of clonidine using yohimbine rauwolscine and corynanthine. Eur. J. Pharmacol., 70, 7-15.
34. URBAN, R., SZABO, B. & STARKE, K. (1994). Is the sympathoinhibitory effect of rilmenidine mediated by alpha-2 adrenoceptors or imidazoline receptors. J. Pharmacol. Exp. Ther., 270, 572-578.
35. 2-adrenoceptors in the cardiovascular effects of moxonidine. Eur. J. Pharmacol., 282, 19-28.
36. VAN ZWTETEN, P.A. (1986). Overview of alpha2-adrenoceptor agonists with a central action. Am. J. Cardiol. 57, 3E-5E.
37. 2-adrenoceptor antagonists of the central sympatho-inhibitory effect of clonidine. Br. J. Pharmacol., 117, 587-593.
38. WINTER, J.C. & RABIN, R.A. (1992). Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination. J. Pharmacol. Exp. Ther., 263, 682-689.
39. YU, A. & FRISHMAN, W.H. (1996). Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension. J. Clin. Pharmacol., 36, 98-111.
40. 2A - AR) mice. Br. J. Pharmacol., 122, 70P.